Intervention Review

You have free access to this content

Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome

  1. Susanne Unverzagt1,*,
  2. Lisa Wachsmuth2,
  3. Katharina Hirsch1,
  4. Holger Thiele3,
  5. Michael Buerke4,
  6. Johannes Haerting1,
  7. Karl Werdan4,
  8. Roland Prondzinsky2

Editorial Group: Cochrane Heart Group

Published Online: 2 JAN 2014

Assessed as up-to-date: 30 JAN 2013

DOI: 10.1002/14651858.CD009669.pub2


How to Cite

Unverzagt S, Wachsmuth L, Hirsch K, Thiele H, Buerke M, Haerting J, Werdan K, Prondzinsky R. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD009669. DOI: 10.1002/14651858.CD009669.pub2.

Author Information

  1. 1

    Martin Luther University Halle-Wittenberg, Institute of Medical Epidemiology, Biostatistics and Informatics, Halle/Saale, Germany

  2. 2

    Carl von Basedow Klinikum Merseburg, Cardiology/Intensive Care Medicine, Merseburg, Germany

  3. 3

    University of Leipzig, Heart Center, Leipzig, 04289, Germany

  4. 4

    Martin Luther University Halle-Wittenberg, Internal Medicine III, Halle (Saale), Germany

*Susanne Unverzagt, Institute of Medical Epidemiology, Biostatistics and Informatics, Martin Luther University Halle-Wittenberg, Magdeburge Straße 8, Halle/Saale, 06097, Germany. susanne.unverzagt@medizin.uni-halle.de.

Publication History

  1. Publication Status: New
  2. Published Online: 2 JAN 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 4]
Figure 4. Survival curves of included trials on levosimendan.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Levosimendan versus control, Outcome 1 All cause mortality distribution.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Levosimendan versus control, Outcome 2 All-cause 30-day mortality rates.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Levosimendan versus control, Outcome 3 All-cause 6-month mortality rates.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Levosimendan versus control, Outcome 4 All-cause 12-months mortality rates.